Literature DB >> 19124515

Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.

Marc Arbyn1, Ina Benoy, Cindy Simoens, Johannes Bogers, Philippe Beutels, Christophe Depuydt.   

Abstract

INTRODUCTION: Before the introduction of vaccination against human papillomaviruses (HPV) as a new strategy of combating cervical cancer, it is required to describe the baseline prevalence of HPV infection as well as the distribution of the different HPV types in the population and among women with cervical lesions.
MATERIALS AND METHODS: Approximately 10,000 liquid cervical cell samples from women, resident of Flanders (North Belgium) and participating in cervical cancer screening, were assessed cytologically and virologically with a multiplex real-time PCR using primers targeting the E6/E7 genes of 16 HPV types. Correlations of HPV infection with age, geographic area, and occurrence of cytologic lesions were assessed.
RESULTS: The prevalence of cytologic abnormalities was atypical squamous cells of undetermined significance (ASC-US), 1.6%; atypical glandular cells (AGC), 0.2%; low-grade squamous intraepithelial lesion (LSIL), 2.6%; atypical squamous cells, HSIL cannot be excluded (ASC-H), 0.3%; and high-grade squamous intraepithelial lesion (HSIL), 1.2%. The frequency of high-risk HPV infections was 11% in women without cytologic abnormalities, 77% in ASC-US, 32% in AGC, 85% in LSIL, and 93% in ASC-H and HSIL. The prevalence of high-risk HPV infection was highest in women of ages 20 to 24 years (29%) and decreased progressively with age. The percentage of women with HSIL in the entire study population attributable to infection with a particular type (AR(pop) %) was highest for HPV16 (32%), followed by HPV31 (22%), HPV39 (11%), and HPV52 (11%). HPV18 was responsible for 7% of the HSIL lesions. Elimination of HPV16 and HPV18 is expected to reduce the prevalence of ASCUS with 24%, AGC with 19%, LSIL with 29%, ASC-H with 31% and HSIL with 37%. DISCUSSION: Compared to other West European studies, the prevalence of HPV infection was considerably higher in cytologically negative women but similar in women with cervical lesions. These differences could be due to the use of a PCR with high analytic sensitivity. These data are relevant for estimating the expected and theoretical levels of vaccine protection offered as vaccinated girls gradually age into the groups from which our observations stem. Further periodic laboratory-based surveys, including genotyping of cervical cell samples and linkage with vaccine registries, are an important resource to address pending questions of the effect of HPV vaccination. Research is warranted to disentangle the causal role of individual HPV types in case of multiple infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19124515     DOI: 10.1158/1055-9965.EPI-08-0510

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  17 in total

1.  Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening.

Authors:  C E Depuydt; I H Benoy; J F A Beert; A M Criel; J J Bogers; M Arbyn
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

2.  Ano-Genital Warts and HIV Status- A Clinical Study.

Authors:  Shashikant Balakrishana Dhumale; Shimpa Sharma; Arvind Gulbake
Journal:  J Clin Diagn Res       Date:  2017-01-01

Review 3.  Monitoring of human papillomavirus vaccination.

Authors:  J Dillner; M Arbyn; E Unger; L Dillner
Journal:  Clin Exp Immunol       Date:  2010-11-09       Impact factor: 4.330

4.  The prevalence and risk factors of human papillomavirus in female sex workers.

Authors:  Gursel Ersan; Sukran Kose; Suheyla Serin Senger; Habibe Gunes; Salim Sehirali; Ilhan Gurbuz
Journal:  Eurasian J Med       Date:  2013-02

5.  Human papillomavirus types distribution in eastern Sicilian females with cervical lesions. A correlation with colposcopic and histological findings.

Authors:  Maria Le Donne; Giuseppe Giuffrè; Carmela Caruso; Piero Antonio Nicotina; Angela Alibrandi; Rosalba Scalisi; Angela Simone; Benito Chiofalo; Onofrio Triolo
Journal:  Pathol Oncol Res       Date:  2013-02-19       Impact factor: 3.201

6.  Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard.

Authors:  Philippe Halfon; Sophie Ravet; Hacène Khiri; Guillaume Penaranda; Carole Lefoll
Journal:  Clin Med Insights Case Rep       Date:  2010-12-16

7.  Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma.

Authors:  Perle Ernoux-Neufcoeur; Mohammad Arafa; Christine Decaestecker; Anaëlle Duray; Myriam Remmelink; Xavier Leroy; Michael Herfs; Joan Somja; Christophe E Depuydt; Philippe Delvenne; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-08       Impact factor: 4.553

8.  Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany.

Authors:  Karl Ulrich Petry; Alexander Luyten; Annika Justus; Angelika Iftner; Sarah Strehlke; Axel Reinecke-Lüthge; Elisabeth Grunwald; Renate Schulze-Rath; Thomas Iftner
Journal:  BMC Infect Dis       Date:  2013-03-13       Impact factor: 3.090

9.  High-risk human papillomavirus infection in HIV-positive African women living in Europe.

Authors:  Deborah Konopnicki; Yannick Manigart; Christine Gilles; Patricia Barlow; Jérome de Marchin; Francesco Feoli; Denis Larsimont; Marc Delforge; Stéphane De Wit; Nathan Clumeck
Journal:  J Int AIDS Soc       Date:  2013-02-14       Impact factor: 5.396

10.  Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.

Authors:  M K Leinonen; A Anttila; N Malila; J Dillner; O Forslund; P Nieminen
Journal:  Br J Cancer       Date:  2013-10-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.